Ozone Therapy

Evidence-Based Benefits of Ozone Therapy

Ozone therapy involves the administration of ozone gas (O3) into the body to treat a variety of diseases. While often considered alternative medicine, a growing body of scientific research, particularly in preclinical and some clinical studies, suggests several potential benefits.

One of the primary mechanisms of action for ozone therapy is its ability to modulate the immune system. Ozone can stimulate the production of cytokines and growth factors, which play crucial roles in immune response and tissue repair. This immunomodulatory effect has led to investigations into its use for autoimmune diseases and chronic infections.

Another key benefit is its potent antimicrobial properties. Ozone is a strong oxidizing agent and can effectively inactivate bacteria, viruses, fungi, and parasites. This makes it a promising adjunctive treatment for various infectious conditions, including infected wounds, dental infections, and even some systemic infections when applied appropriately.

Furthermore, ozone therapy has demonstrated potential in improving circulation and oxygen delivery. It can enhance the flexibility of red blood cells, allowing them to navigate smaller capillaries more effectively, and can also stimulate the production of 2,3-bisphosphoglycerate (2,3-BPG), which facilitates oxygen release from hemoglobin to tissues. These effects are particularly relevant for conditions involving ischemia and poor circulation.

Anti-inflammatory and antioxidant-boosting effects are also attributed to ozone therapy. While ozone itself is an oxidant, its controlled administration at therapeutic doses can activate the body’s endogenous antioxidant defense systems, leading to a net reduction in oxidative stress and inflammation over time. This makes it a subject of interest for chronic inflammatory conditions and pain management.

Intravenous ozone therapy

Intravenous ozone therapy, is a systemic application method based on the low-dose ozone concept developed by the German Medical Society for the Use of Ozone in Prevention and Therapy. This approach emphasizes hormesis, where low doses of ozone induce moderate oxidative stress to activate antioxidant defenses, improve circulation, and modulate immune responses without toxicity. The protocol prioritizes safety, using ozone-resistant materials and aseptic techniques to avoid complications like embolism or infection. It is complementary to conventional treatments and is commonly used in Germany for circulatory and immune-related conditions. Note that ozone therapy remains controversial in some regions due to limited large-scale randomized trials, but PubMed-indexed studies support its potential in areas like pain management, wound healing, and immunomodulation.

Indications

Based on German guidelines, is indicated for:

  • Arterial circulatory disturbances (e.g., peripheral, cerebral/post-stroke, ocular retinopathies, inner ear issues like acute hearing loss or tinnitus).
  • Angiopathies, particularly diabetic angiopathy.
  • Viral diseases (e.g., hepatitis B/C, herpes simplex/zoster).
  • General immune deficiencies (e.g., asthenia, geriatric conditions, environmental medicine).
  • Complementary oncology support (e.g., mitigating chemotherapy/radiation side effects).
  • Chronic inflammatory processes (e.g., orthopedics, rheumatology, rheumatoid arthritis in acute or non-acute phases).

PubMed evidence aligns with these, showing benefits in musculoskeletal pain (e.g., via antioxidant regulation), infections, inflammation, and quality-of-life improvements in chronic conditions.

Contraindications

  • Glucose-6-phosphate dehydrogenase deficiency (favism, acute hemolytic anemia).
  • Uncontrolled hyperthyroidism.
  • First trimester of pregnancy.
  • Leukemia (not indicated for MAH).

Additional precautions from PubMed reviews include avoiding in patients with severe cardiovascular instability or recent myocardial infarction, due to rare risks like embolism.

Ozone Concentrations and Dosages

  • Concentration in Ozone/Oxygen Mixture: 10–30 μg/ml (maximum 40 μg/ml for systemic use; avoid ≥80 μg/ml to prevent hemolysis >10%).
  • Biologically Effective Concentration in Blood: 10–20 μg/ml (up to 40 μg/ml).
  • Total Ozone Dosage per Treatment: 500–1,500 μg (maximum 2,000–4,000 μg; standard low-dose: 500–1,000 μg for 50 ml blood).

PubMed studies often use similar ranges (e.g., 50 μg/ml in 200 ml blood for immunomodulation or pain relief), with evidence of improved mitochondrial bioenergetics after 1–2 sessions.

Treatment Frequency and Course

  • Initial: 2 sessions per week.
  • Standard Course: 10 treatments, repeatable 2–3 times/year.
  • Acute Conditions: Daily initially, then weekly.
  • Maintenance: Adjust based on response (e.g., 1–2 sessions/week for chronic inflammation).

PubMed data suggests 5–18 sessions (e.g., 2/week for 6 weeks) for benefits in quality of life or cerebral blood flow.

Safety and Mechanisms

Low-dose MAH is safe when protocols are followed; no serious adverse effects in compliant applications. Mechanisms include formation of “ozone peroxides” that upregulate antioxidants (e.g., SOD, GSH), reduce oxidative stress markers (e.g., MDA), and enhance oxygen metabolism. PubMed reviews confirm immunomodulatory effects without toxicity at these doses, though rare neurological risks (e.g., embolism) highlight the need for trained practitioners.

This protocol should only be performed by qualified medical professionals in compliance with local regulations. Consult a physician for personalized advice.

Intravenous ozone therapy, primarily via Major Autohemotherapy (MAH), is generally considered safe at low therapeutic doses (10–40 μg/ml) when performed according to established protocols, particularly those from German medical societies. Systematic reviews and clinical studies, including those from PubMed-indexed sources, report a low incidence of adverse events, often comparable to or lower than control groups. However, rare severe complications can occur, especially with improper technique, high doses, or in vulnerable patients.

Usual (Common/Mild) Side Effects

These are typically transient, self-limiting, and occur in a minority of cases:

  • Mild fatigue, headache, or tiredness post-treatment.
  • Nausea, dizziness, or lightheadedness.
  • Minor local reactions at the venipuncture site (e.g., ecchymosis, hematoma, or transient pain).
  • Occasional palpitations, chest tightness, or hot flushes (rarely reported in older protocols; minimized with modern glass/vacuum systems and gradual dose escalation).
  • In some studies (e.g., postherpetic neuralgia or combined therapies), symptoms like somnolence or mild gastrointestinal upset, but no significant difference from controls.

PubMed evidence indicates these are infrequent and do not usually lead to treatment discontinuation. Incidence is often <5–10% in compliant applications, with many reviews noting no serious adverse effects overall.

Severe/Rare Side Effects

These are uncommon but documented in case reports or specific contexts:

  • Embolic events leading to ischemic strokes, syncope, seizures, or neurological deficits (e.g., one case of multiple infarcts post-IV ozone, attributed to possible air/oxygen embolism).
  • Hyperkalemia or sinus arrest (in patients with chronic kidney disease).
  • Rare allergic-like reactions (e.g., rash, hypotension) or methemoglobinemia (when combined with other therapies).
  • Infections or septicemia (extremely rare, linked to contamination or malpractice).
  • Other isolated reports: myocardial infarction, fulminant septicemia (from disc herniation treatment variants), or transient oxidative stress markers.

Severe events are often tied to non-standard administration (e.g., direct gas injection, PVC bags, or high concentrations). Modern low-dose MAH protocols show very low risk (e.g., 0.0007% overall incidence in historical data), with many studies reporting no serious complications.

Expected Benefits

MAH is used complementarily for conditions like circulatory disorders, chronic inflammation, pain syndromes, and immune support. Evidence from PubMed-indexed studies and reviews (including German-influenced protocols) suggests:

  • Pain reduction — Significant improvements in chronic pain (e.g., fibromyalgia, low back pain, postherpetic neuralgia, musculoskeletal issues), with sustained effects (e.g., ≥50% reduction in VAS scores, better than controls in some meta-analyses).
  • Improved quality of life and functionality — Enhanced sleep, reduced fatigue, better mood, and physical function (e.g., in fibromyalgia, cancer-related symptoms, or chronic conditions).
  • Anti-inflammatory and antioxidant effects — Upregulation of endogenous antioxidants, reduced oxidative stress markers, and immunomodulation.
  • Other potential benefits — Improved mitochondrial bioenergetics, better outcomes in infections (e.g., adjunct in COVID-19 or hepatitis), wound healing support, and complementary role in oncology (e.g., mitigating side effects) or vascular issues (e.g., Raynaud’s in scleroderma).

Benefits are often seen after 5–10 sessions, with effects lasting months in responsive patients. Systematic reviews highlight strong evidence for pain control (especially low back/knee osteoarthritis) and safety as an integrative approach, though larger RCTs are needed for some indications.

This information draws primarily from PubMed sources, including systematic reviews, clinical trials, and case reports. Ozone therapy remains controversial in some regions due to limited high-level evidence and rare risks; it should only be administered by trained professionals following strict guidelines. Consult a qualified physician for individualized assessment.

Here is a selection of relevant PubMed-indexed references on intravenous ozone therapy drawing from studies often aligned with German/European protocols or low-dose concepts. These include clinical trials, reviews, and observational data supporting mechanisms, safety, and applications (e.g., pain, inflammation, circulatory issues, fibromyalgia, infections).

  1. Effects of Major Ozone Autohemotherapy on Physical Functionality and Quality of Life in Fibromyalgia Syndrome: A Prospective Cross-sectional Study (2021)
  2. Effectiveness of ozone therapy in addition to conventional treatment on mortality in patients with COVID-19 (2021)
  3. Treatment of Femoral Head Osteonecrosis with Ozone Therapy: Pilot Trial of a New Therapeutic Approach (2022)
  4. How Ozone Applications in the Blood Can Influence Clinical Therapy Success via the Modulation of Cell Biology and Immunity (2023)
  5. Long-term improvement in refractory headache following ozone therapy (2013)
  6. The effects of oxygen-ozone therapy on regulatory T-cell responses in multiple sclerosis patients (2021)
  7. Ozone therapy: A clinical review (2011)
  8. A pilot randomized controlled trial of major ozone autohemotherapy for patients with post-acute sequelae of COVID-19 (2024)

For German or European authorities/guidelines on medical ozone therapy (focusing on low-dose MAH protocols, safety, and standardization):

  • Ärztliche Gesellschaft für Ozonanwendung in Prävention und Therapie (German Medical Society for the Use of Ozone in Prevention and Therapy) – The primary German authority since 1972 (renamed 1993), providing guidelines, training, and evidence classification for MAH. Official site: https://www.ozongesellschaft.de/ (English page: https://ozongesellschaft.de/ozone-society.html). They publish updated guidelines (e.g., 2012 low-dose concept in Ozone: Science & Engineering) and coordinate with European societies.
  • European Cooperation of Medical Ozone Societies (EUROCOOP) – Umbrella for standardization across Germany, Austria, Switzerland, Italy, etc. References often link back to the German society’s protocols.

These sources emphasize low-dose (10–40 μg/ml), aseptic techniques, and complementary use. Ozone therapy is practiced under “freedom of therapy” in Germany (no strict federal drug authorization required for physician application), but always consult a qualified practitioner and local regulations. Evidence remains mixed in some mainstream views, with calls for larger RCTs.

Scroll to Top